American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
ASCO 2023 Prostate Cancer
- ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
- ASCO 2023: Discussant: Advanced Urothelial Carcinoma: Striking a Balance of Efficacy and Safety
- ASCO 2023: Discussant: Hitting the Sweet Spot with Radiation and Androgen Deprivation
- ASCO 2023: Prognostic Impact of PSA Nadir (N) ≥0.1 ng/mL Within 6 Months After Completion of Radiotherapy for Localized Prostate Cancer: An Individual Patient-Data Analysis of Randomized Trials from the ICECAP Collaborative
- ASCO 2023: Discussant: Looking Ahead: Novel Agents in Castration-Resistant Prostate Cancer
ASCO 2023 Bladder Cancer
- ASCO 2023: Discussant: The Power of Patients' Experiences to Inform Therapeutic Decisions
- ASCO 2023: Discussant: Optimizing Outcomes in Upfront Management of Localized Bladder Cancer
- ASCO 2023: FGFR3 Alterations in PROOF 302: A Phase III Trial of Infigratinib (BGJ398) as Adjuvant Therapy in Patients with Invasive Urothelial Carcinoma
- ASCO 2023: Long-Term Outcomes of Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
- ASCO 2023: ADVANCED-2: Phase 1b/2 Dose Expansion, Open-Label Study to Evaluate Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade NMIBC
ASCO 2023 Kidney Cancer
- ASCO 2023: Phase 1b/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC
- ASCO 2023: Efficacy of First-Line Immunotherapy - Based Regimens in Patients with Sarcomatoid And/or Rhabdoid Metastatic Non-Clear Cell Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consort
- ASCO 2023: Phase II Study of Cabozantinib with Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma with Variant Histologies
- ASCO 2023: First-Line Lenvatinib + Pembrolizumab Treatment Across Non-Clear Cell Renal Cell Carcinomas: Results of the Phase 2 KEYNOTE-B61 Study
- ASCO 2023: CABOSUN II: Results from a Phase 2, Open-Label, Multi-Center Randomized Study of Cabozantinib vs. Sunitinib for Non-Clear Cell RCC
ASCO 2023 Testicular and Penile Cancer
- ASCO 2023: Primary RPLND in Seminoma Stage IIA-IIC ≤3cm: Combined Results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne
- ASCO 2023: Molecular Drivers of Organotropism and Cisplatin Resistance in Germ Cell Tumors
- ASCO 2023: Long Term Follow-up Analysis of Plasma miR371 Expression to Detect Early Relapse in Patients with Clinical Stage I Testicular Germ Cell Tumors on Surveillance
- ASCO 2023: Hospital Anxiety and Depression Scale Score Trends Among Testicular Cancer Survivors: A Longitudinal Study